Podcast appearances and mentions of jyoti patel

Dr. Jyoti Patel is back on the podcast to discuss the updates to the living guideline on therapy for stage IV NSCLC with driver alterations. She shares updated recommendations in the first- and second-line settings for patients with stage IV NSCLC and classical EGFR mutations, and the impact of these updates for clinicians and patients. We also look to the future to discuss ongoing developments in the field. Read the full living guideline update “Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3” at www.asco.org/living-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/living-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-24-02785     Brittany Harvey: Welcome to the ASCO Guidelines Podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges and advances in oncology. You can find all the shows including this one at asco.org/podcasts.   My name is Brittany Harvey and today I'm interviewing Dr. Jyoti Patel from Northwestern University, co-chair on “Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3.” It's great to have you back on the show today, Dr. Patel. Dr. Jyoti Patel: Thanks so much. Happy to be here. Brittany Harvey: And then before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Patel, who has joined us here today, are available online with the publication of the guideline and in the Journal of Clinical Oncology, which is linked in the show notes. So then, to dive into the content of this update, Dr. Patel, this clinical practice guideline for systemic therapy for patients with stage IV non small cell lung cancer with driver alterations is living, meaning that it's continuously reviewed and updated. So what data prompted this latest change to the recommendations? Dr. Jyoti Patel: Thanks so much. So it's really been an exciting time in the treatment of EGFR lung cancer, particularly this past year has required us to rethink approaches to front- and second-line therapy. In this particular update, we examined what patients in the front-line setting may be offered by their clinicians. And so we're talking about the population of classical EGFR mutations, so exon 19 and exon 21 L858R substitution. And so certainly for this population, osimertinib has a high level of evidence and should be offered to all patients at the time of diagnosis when they present with advanced disease. Our last update included a recommendation that patients could also get platinum doublet chemotherapy with osimertinib or osimertinib alone. This current recommendation also introduces another alternative therapy and that's the combination of amivantamab plus lazertinib. And so now, clinicians are faced with three really good options for their patients with EGFR exon19 deletion or L858R. Brittany Harvey: It's great to hear that there's this advance in the space, particularly for patients with these classical EGFR mutations that you mentioned. So what should clinicians know as they implement these new first-line recommendations? Dr. Jyoti Patel:  I think it's become more complex than ever. Certainly, we know again that patients should get osimertinib in the frontline setting. But we've been kind of stuck at progression-free survival that's between a year and a half and two years. And so we've really been looking at opportunities to intensify therapy. So one could certainly be with chemotherapy or switching over to amivantamab, the bispecific antibody that targets EGFR and MET plus lazertinib, an oral TKI that's very similar in structure to osimertinib. And when you're talking to a patient, it's really a conversation about balancing efficacy with toxicity. Unfortunately, as we know, there aren't that many free lunches. And so if we think about what a patient is hoping for in their therapy and how we can further personalize treatment options, really is important to look at some of the analyses for this study. So in the study of amivantamab plus lazertinib, we know that there were increased toxicities with a combination of both therapies. In fact, up to 75% of patients had over grade 3 toxicities, versus about 43% of patients with osimertinib monotherapy. And we know if we look back at FLAURA2, almost two thirds of patients with osimertinib and chemotherapy had grade 3 toxicities, compared to 27% of patients with osimertinib alone. So we certainly see an increase in toxicities. Then we have to ask ourselves, are those paper toxicities or ones that really impact patients? And we know that amivantamab, for example, causes significant cutaneous toxicities. With both of these therapies, whether it's chemotherapy or adding amivantamab, there's the burden of infusional visits and increased time in the doctor's office. Certainly with chemotherapy, there can be an increased incidence of myelosuppression. And so when we're thinking about advising our patients, certainly we need to talk about the toxicities. But one thing that we've been able to do is to look at the patients that were included in this trial. And what we really find is that in higher risk cohorts, particularly those that we know historically have done less well with standard osimertinib, so patients, for example, with CNS metastasis, for those patients with co-mutations, it may be that that additive benefit is significant. And so one example I think would be from the MARIPOSA study, again, the study of amivantamab and lazertinib versus chemotherapy. What we can say is that patients who had co-mutations, so patients with EGFR mutations as well as TP53, lazertinib and amivantamab led to a hazard ratio of 0.65 compared to osimertinib alone. So that was 18.2 months versus 12.9 months. And so this may be really important to patients. And we also see conversely that patients with wild type TP53, so those patients who didn't have the mutation, probably had equivalent survival regardless of therapy. So certainly, we need to prospectively study some of these high-risk cohorts. We've only seen progression-free survival in these studies. And so at this juncture, we can advise our patients about toxicity, the improvements in certain categories of progression-free survival, but we really still don't know how this pans out in overall survival. In many of these studies, all patients do not necessarily cross over to the study arm and so they may have lost the benefit of subsequent therapy. Brittany Harvey: Absolutely. It's very important to talk about that balance of benefits and risks and particularly those toxicities that you discussed. So I appreciate reviewing that recommendation and the considerations for clinicians for first-line therapy. This update also included a second-line treatment update. What is that update for patients with EGFR alterations? Dr. Jyoti Patel: So this is where it gets super tricky because we have a frontline option with amivantamab and now we've had an update in the second line option. So what we said is that for patients who have progressed on an EGFR TKI, and in the United States, certainly that's predominantly osimertinib, or those in other parts of the world that may have gotten an earlier generation TKI, but do not have evidence of T790M or other targetable mutations, we can offer patients chemotherapy with or without amivantamab. And so certainly we have seen that this again leads to improved survival. There have also been a number of studies looking at incorporation of PD-L1 and anti-VEGF therapies. And what we can say, I think pretty clearly is that multiple phase 3 trials have really shown no benefit of the addition of PD-1 to platinum chemotherapy. But there are some emerging bispecific antibodies that may target PD-1 as well as VEGF, or combinations of antibodies that target both of those pathways that may improve outcome. At this juncture, I think we feel that the evidence surrounding chemotherapy plus amivantamab is strongest, but there is certainly work in this space that will be of interest. Now, what happens if your patient received amivantamab and lazertinib in the frontline setting and then has progression? And so we're trying to understand resistance mechanisms and opportunities for treatment. What the panel decided to recommend, based on the available evidence, was that certainly those patients should get platinum-based chemotherapy, but there may also be a role for antivascular endothelial growth factor targeting therapy such as bevacizumab in patients in whom it would be safe. Brittany Harvey: Great. I appreciate you detailing those recommendations when it gets complicated in the second-line setting. So what should clinicians know as they implement these second-line recommendations too? Dr. Jyoti Patel: So certainly the frontline setting matters significantly. So if a patient gets osimertinib in the frontline setting, we generally suggest that patients undergo repeat testing to see if they have another targetable mutation. If they don't, then I think preferred therapy would be chemotherapy with or without amivantamab. And amivantamab leads to a significant improvement in progression-free survival and response rate at the cost of increased risk of toxicity. For patients who get FLAURA2 in the frontline setting, chemotherapy plus osimertinib, it's a little bit of an unclear space. Those patients most likely would get docetaxel with or without ramucirumab. But there are other agents that we hope to have available to our patients in the near future. For patients who receive amivantamab and osimertinib, we recommend that those patients get chemotherapy probably with anti-VEGF as demonstrated by multiple trials that have shown the improved progression-free survival with introduction of an anti-VEGF agent. And we've seen evidence of amivantamab in the third line setting, so it is likely that this question about sequencing really takes center stage in our next set of trials. When you're talking to a patient, I think again, it's absolutely important to discuss: What are their goals? How symptomatic or how fast is their progression? Are there ways in which patients may benefit from spot treatment oligoprogression such as radiation? When is the right time for introduction of amivantamab and when do we think patients need chemotherapy? Is it up front or predominantly in the second-line setting? Brittany Harvey: Definitely. And then you've just touched on the goals of treatment for individual patients. So in your view, what does this update mean for patients with stage IV non-small cell lung cancer and an EGFR alteration? Dr. Jyoti Patel: For patients, this is a time in which shared decision making really needs to take center stage. So our best patients are those patients that are best informed not only about their disease but also have a good understanding about what is important to them and their families in terms of care. And so bringing that shared understanding to the table again helps us think about this particular cancer as more of a journey rather than just a one off treatment. Therapy will hopefully be prolonged, and so it's absolutely important that we address toxicities, make therapies more tolerable, again, with the shared goal of living long and living well. Brittany Harvey: Absolutely. Those are key points to making sure that patients are living both longer and have a good quality of life during that time as well. So then, before you mentioned the possibility of future sequencing trials and other ongoing developments. What additional studies or future directions is the panel examining for future updates to this living guideline? Dr. Jyoti Patel: So certainly we're thinking about trials that look at, for example, cfDNA clearance. So are there patients that do well and can we detect that early on without having to intensify therapy on day 1 so it may be that we add chemotherapy a little bit later. I think really exciting are some of the new bispecific. The HARMONi-A trial was a trial in China of a novel bispecific, ivonescimab. And this drug targets both PD-1 and VEGF and it was combined with chemotherapy. And this trial found almost a doubling of progression-free survival with this drug in combination chemotherapy in an EGFR patient population. That study is being planned and being run in the United States to see if we have similar outcomes with a more diverse population. So certainly that's exciting. There are a number of antibody drug conjugates that are being studied in the post-chemotherapy setting as well. And I think we'll likely soon see a better understanding of what co-mutations and burden of disease really mean when we're thinking about assigning treatment. So which patients, again, need intensification of therapy and which patients may do really well on just an oral agent that they're taking at home with more tolerable toxicity than dual treatment. Brittany Harvey: Yes, we'll look forward to continued developments in these fields and seeing some of those studies come to fruition. So with that, I want to thank you for your work to rapidly and continuously update this guideline, and thank you for your time today, Dr. Patel. Dr. Jyoti Patel: Thanks so much, Brittany. It's really an exciting time for lung cancer and we hope that these updates really help physicians decide the best treatments for their patients. Again, it's a rapidly evolving landscape which is fantastic, but it does become more cumbersome to stay ahead of the literature. Brittany Harvey: Definitely. And so we appreciate your time and the panel's time spent reviewing this literature and providing this much needed information to clinicians everywhere. So finally, thank you to all of our listeners for tuning into the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/living-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app available in the  Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Amardeep Parmar (https://www.linkedin.com/in/amardeepsparmar) from The BAE HQ (https://www.linkedin.com/company/the-bae-hq) welcomes Jyoti Patel, CEO and Founder of Red Rickshaw and FeastBoxThis podcast episode explores Jyoti Patel's entrepreneurial journey from co-founding Red Rickshaw and Feastbox to angel investing, focusing on the interplay between psychology, business growth, and cultural innovation.Message from our headline partners:From the first-time founders to the funds that back them, innovation needs different. HSBC Innovation Banking is proud to accelerate growth for tech and life science businesses, creating meaningful connections and opening up a world of opportunity for entrepreneurs and investors alike. Discover more at https://www.hsbcinnovationbanking.com/________Show Notes: 00:00 - Intro02:01 - Jyoti's childhood ambition of becoming an FBI agent and early passion for psychology.03:07 - Reflections on family, cultural influences, and first trip to India.05:13 - Choosing psychology as a career and studies.06:47 - Transition to business psychology and first career steps.08:30 - Jyoti's curiosity about building businesses from her management consulting experience.09:55 - The catalyst for starting Red Rickshaw: personal frustration with Asian grocery shopping.12:02 - Initial steps in launching Red Rickshaw, identifying product-market fit.14:58 - Challenges in building the business, including logistics and product sourcing.17:11 - Early hires and managing logistics with a full-time job.19:43 - Reaching a million in sales and deciding to go full-time.21:42 - Raising VC funds and scaling the business.25:50 - Launching Feastbox as an extension of Red Rickshaw.29:01 - Lessons learned from Red Rickshaw applied to Feastbox operations.31:02 - Exiting both businesses and transitioning to new ventures.32:46 - Exploring psychology's role in consumer behavior and decision-making.35:32 - Current focus: angel investing and helping startups expand to the US.38:48 - Advice for entrepreneurs on geographic expansion.Jyoti Patel: https://www.linkedin.com/in/jyoti-patel-53ba37a/Website:https://jyotipatel.me/

What happens when the demands of a high-pressure career in medicine overshadow your own health? Dr. Jyoti Patel shares her raw and compelling journey from being a dedicated integrative pediatrics and internal medicine doctor to a thyroid cancer survivor who had to learn the hard way about the importance of self-care. At just 29, Jyoti's diagnosis and subsequent metastatic recurrence forced her to reevaluate her life, pushing through surgery and relentless work culture to find a new balance. Through her story, listeners will gain insights into the critical issues of self-neglegence and the urgent need for healthcare professionals to prioritize their well-being.Jyoti's journey didn't stop at surviving cancer; she had to navigate the challenges of pregnancy and career pressures, with a poignant story about a disheartening interaction with her boss prompting a profound reassessment of her self-worth. In a riveting metaphorical recount, Jyoti describes the experience of being trapped in a ravine, illustrating the significance of self-reflection and mindfulness. This episode offers valuable lessons on setting personal boundaries and understanding behavior patterns, ultimately encouraging listeners to pause, reflect, and create their own path to healing and growth. Tune in to be inspired by Jyoti's resilient spirit and transformative message.Guest Bio:Jyoti PatelTriple board-certified and a Fellow of the American College of Physicians and the American Academy of Pediatrics, Dr. Patel practices Integrative Pediatrics and Internal Medicine in Scottsdale, Arizona. Acknowledged as one of the TOP DOCS by Phoenix Magazine in 2009, 2016, and 2022, she has received accolades such as ACP Internist of the Year in 2011 and the Women In White Coats Hero Award in,2019. Beyond her medical expertise, she played a pivotal role in establishing a community garden in Fountain Hills. Dr. Patel's personal journey, marked by a cancer diagnosis at 29, ignited a profound passion for holistic health. Advocating for preventive care and health education, she extends her commitment beyond traditional medical boundaries. Challenging the reactive nature of the healthcare system, Dr. Patel emphasizes addressing the root causes of disease. Her belief in empowering patients to take control of their health is evident, providing insights and resources for healthier and happier lives.Follow Jyoti on LinkedIn:https://www.linkedin.com/in/jyoti-patel-84466017b Connect with Theresa and Ivana: Websites: Theresa, True Strategy Consultants: https://tsc-consultants.com/ Ivana, Courageous Being: https://www.courageousbeing.com/ Instagram: Ivana: https://www.instagram.com/courbeing/ Theresa: https://www.instagram.com/tscconsultants/ LinkedIn: Step into the Pivot: https://www.linkedin.com/showcase/step-into-the-pivot/ Theresa: https://www.linkedin.com/in/tree-conti/ Ivana: https://www.linkedin.com/in/ivipol/

Send us a Text Message.In this episode, Dr. Jyoti Patel, an integrative and functional medicine expert, shares her personal journey into holistic health. Dr. Patel recounts her battle with cancer, illustrating the dangers of ignoring health warnings due to career pressures. Her story is a crucial reminder for women to prioritize self-care and empowerment.We delve into alarming health statistics affecting women, including higher rates of osteoporosis, dementia, IBS, depression, anxiety, and heart disease. Dr. Patel shares a personal misdiagnosis story, highlighting the need for comprehensive testing and healthcare advocacy. We discuss the impact of chronic stress and high cortisol levels on women's health and offer practical stress management tips, including vagal toning exercises. We also examine hormonal imbalances in women and their overall health impact. From hormonal dysregulation symptoms to the role of nutrition and the debate on birth control, we advocate for individualized, compassionate care. Dr. Patel emphasizes the importance of personalized hormone testing and stress management, including wearable technology for real-time health monitoring.Join us for strategies to maintain optimal wellness and the importance of continuous learning and personal growth. Don't forget to subscribe and leave a review to help us share this vital information. Chapters:(00:00) Empowering Women's Health Through Integrative Medicine(08:31) Stress Impact on Women's Health(17:55) Women's Health Empowerment Through Integrative Medicine"(27:56) Holistic Approach to Hormonal Imbalances(37:14) Hormone Testing and Stress Management Links:aimsforwellness.comJoin Over 18,000 Leading Medical Professionals and Become a Vibrant Wellness Provider Today! (https://portal.vibrant-wellness.com/#/sign-up)

Dr. Jyoti Patel discusses the latest update to the stage IV NSCLC with driver alterations living guideline, specifically for patients with EGFR or ROS1 alterations. She shares the latest recommendations based on recently published evidence, such as the FLAURA2, MARIPOSA-2, and TRIDENT-1 trials. Dr. Patel talks about how to choose between these new options and the impact for patients living with stage IV NSCLC, as well as novel drugs the panel is monitoring for future guideline updates. Read the full living guideline update “Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.1” at www.asco.org/living-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at www.asco.org/living-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO.24.00762  Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges and advances in oncology. You can find all the shows, including this one at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Jyoti Patel from Northwestern University, co-chair on, “Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.1.”  Thank you for being here today, Dr. Patel. Dr. Jyoti Patel: Thanks so much.   Brittany Harvey: Then, before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Patel, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes.  So then to dive into the content of why we're here today, Dr. Patel, this living clinical practice guideline for systemic therapy for patients with stage four non-small cell lung cancer with driver alterations is being updated on a regular basis. So what prompted the update to the recommendations in this latest update?  Dr. Jyoti Patel: This recent update, I think, absolutely reflects how quickly the science is changing. The landscape of treatment options for patients with advanced non-small cell lung cancer is evolving so rapidly, and guidelines from even six months ago don't address some of the newest approvals and newest data and the newest clinical scenarios that we're presented with when we see patients. I think it's harder because before there was usually a single answer, and now there are a number of scenarios, and we hope that the guideline addresses this. Brittany Harvey: Absolutely. The panel's had a lot of data to review as you keep this guideline up to date.  So then this latest update addresses updates to both EGFR and ROS1 alterations. So starting with EGFR, what are the updated recommendations for patients with stage four non-small cell lung cancer and an EGFR exon 19 deletion or exon 21 L858R substitution?  Dr. Jyoti Patel: So for patients with classical driver mutations in EGFR, our recommendation remains that patients should be offered osimertinib. We now also have data to support intensification of therapy with osimertinib and chemotherapy. The FLAURA2 trial was a global randomized study in which patients with classical mutations were assigned to receive either osimertinib or osimertinib with doublet chemotherapy. The trial showed that progression free survival was longer with osimertinib plus chemotherapy with a hazard ratio that was pretty profound, 0.62. In patients who had CNS metastasis as well as patients with L858R mutations, this benefit remained and was perhaps even greater. Now the study remains immature in terms of OS. What we can say is that chemotherapy adds toxicity, so the inconvenience of 13 weekly infusions, expected toxicities from chemotherapy of myelosuppression and fatigue. I think this- we'll continue to watch as the study matures to really see the OS benefit, but certainly intensification in the frontline setting is an option for patients.  The other major update was for second and subsequent line therapy for these patients with EGFR mutations. Another important trial, a study called MARIPOSA-2, was published in the interim, and this was for patients who had received osimertinib in the frontline setting. Patients were randomized to one of three arms. The two arms that are most relevant for us to discuss are chemotherapy with amivantamab or chemotherapy alone. Chemotherapy with amivantamab was associated with an improvement in progression free survival with a hazard ratio of 0.48 as well as improvements in response rate with almost a doubling of response rate to the mid 60%. There was certainly an increase in AEs associated with amivantamab, primarily rash and lower extremity edema and importantly infusion reaction. Based on this data, though in the superior PFS and response rate, we've said that patients after osimertinib should be offered chemotherapy plus amivantamab. Patients may opt for chemotherapy alone because of the toxicity profile, but this recent update is reflective of that data. Brittany Harvey: Excellent. Thank you for reviewing those updated recommendations and the supporting evidence behind those recommendations. I think that's important to the nuance and the toxicity associated with these new recommendations as well.   So then, following those recommendations, what are the updated recommendations for patients with stage four non-small cell lung cancer and a ROS1 rearrangement? Dr. Jyoti Patel: ROS1 fusions have been noted in a small but important subset of patients. We now reflect multiple new options for patients. Traditionally, crizotinib was the primary drug that was recommended, but we now have two very active drugs, repotrectinib, and entrectinib, that have both been FDA approved. Repotrectinib was approved based on a study called the TRIDENT-1 trial. In this study, patients who were treatment naive, who had not received a prior TKI, had a response rate of 79% and a long duration of response over 34 months. For patients who had received prior TKIs, so primarily crizotinib, the response rate was lower at 38%. But again, very clinically meaningful. Repotrectinib has known CNS activity, so it would be the favored drug over crizotinib, which doesn't have CNS penetration. The decision between entrectinib and repotrectinib is one, I think, based on toxicity. Repotrectinib can cause things like dizziness and hypotension. Entrectinib can cause weight gain, and also has CNS effects. Brittany Harvey: Appreciate you reviewing those recommendations as well.  So then you've already talked a little bit about this in terms of deciding between some of the options. But in your view, what should clinicians know as they implement these new recommendations, and how do these new recommendations fit into the previous recommendations? Dr. Jyoti Patel: So there's an onslaught of new data, and certainly many of us want to remain at the front of our fields and prescribe the newest drug, our most effective drug, to all of our patients. But for the person living with cancer and in the practice of medicine, I think it's much more nuanced than that. For example, for a patient with an EGFR mutation exon deletion 19, the expectation is that osimertinib will have a deep and durable response. Certainly a patient will eventually have progression. I think the decision about intensification of therapy and chemotherapy on the onset really has to do with how much the patient is willing to deal with the inconvenience of ongoing chemotherapy, the uncertainty about what comes next after progression on chemotherapy. It may be, though, that a patient may very much fear progressive disease, and so that inconvenience is lessened because anxiety around feeling like they're doing everything for their cancer is diminished by intensification of therapy. Others who may have a large volume of disease or profoundly symptomatic, or who have L858R or brain metastasis it may make sense to give chemotherapy again, we're improving the time until progression significantly by combination therapy. Brittany Harvey: Definitely those nuances are important as we think about which options that patients should receive, along with shared decision making as well.  So then what do these new options mean for patients with EGFR or ROS1 alterations? Dr. Jyoti Patel: It's fantastic for patients that there are multiple options. It's also really hard for patients that there are multiple options, because then again, we have to really clarify aims of therapy, identify what's really important in patient experience and the lived importance of treatment delivery and the burden of treatment delivery. Now more than ever, oncologists have to know what's new and exciting. But patients have to be willing to ask and participate in the shared decision making - understanding their cancer and understanding that their options are absolutely important. As patients start making their decisions, we have the data just in terms of trial outcomes. I think we're now trying to understand the burden of treatment for patients. And so that piece of communicating financial toxicity, long term cumulative lower grade toxicity is going to be more important than ever. Brittany Harvey: Absolutely. It's great to have these new options, and those elements of communication are key to ensuring that patients meet their goals of care.  So then finally, as this is a living guideline, what ongoing research is the panel monitoring for future updates to these recommendations for patients with stage four non-small cell lung cancer with driver alterations? Dr. Jyoti Patel: It's certainly been an exciting time, and that's primarily because we've been able to build on years of foundational science and we have new drugs. Patients have been willing to volunteer to go on clinical trials and to think about what treatment options may be best. Now, the work really comes on seeing the longer term outcomes from these trials. So looking at these trials for overall survival, we want to also better identify which patients will benefit the most from these treatments and so that might be additional biomarker analysis. So it may be that we can identify patients that may need intensification of therapy based on tumor factors as well as patient factors as well in those patients in whom we can de-escalate treatment. I think there are a number of new compounds that are in the pipeline. So fourth generation EGFR TKIs are certainly interesting. They may be able to overcome resistance for a subset of patients who progress on osimertinib. We also think about novel drugs such as antibody drug conjugates and how they'll fit into our paradigm with osimertinib or after carboplatin-based doublets. Brittany Harvey: Definitely. We'll look forward to both longer term readouts from the current trials and new trials in this field to look at additional options for patients.  So I want to thank you so much for your time today, Dr. Patel, and thank you for all of your work to keep this living guideline up to date. Dr. Jyoti Patel: Great. Thanks so much, Brittany. It really is an exciting time for people who treat lung cancer and for patients who have lung cancer. We certainly have a long way to go, but certainly the rapid uptake of these guidelines reflect the progress that's being made.  Brittany Harvey: Absolutely. And just a final thank you to all of our listeners for tuning into the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/living-guidelines.  You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

Welcome to a new episode of Get Creative. In this episode Jade Jarvis sits down with Jyoti Patel, a member of the SubTo and Gator communities, to tell us more about her journey into the world of creative real estate. With a heart full of determination and a mindset geared towards action, Jyoti shares the incredible story of her first SubTo deal in Holly Springs, North Carolina. From leveraging the power of community to executing deals with no money out of pocket, Jyoti's adventure is proof of what's possible when you dive into creative finance.   Highlights:   "I just was like swallowed up by the information that was given and just couldn't wait to get that first deal."   "You can do this every week if you wanted to. But you're not going to do it without the community, that's for sure."   "Take action, make moves, bold moves, right? I mean, these are bold moves... And it's a scalable model, just do it. Take action."   Timestamps: 00:00 - Jyoti Patel's Creative Finance Journey 01:06 - The Power of Community in Real Estate Investing 02:58 - Discovering a SubTo Deal in Holly Springs 04:18 - Buying Sight Unseen: Confidence in Location 05:27 - Exploring Lease to Own Options for Property 07:48 - The Advantage of Having Transaction Coordinators 11:27 - Leveraging Community for Funding and Support 14:11 - The Impact of Sub Two and Gator on Personal Growth 17:21 - Building Trust and Connections Within the Community 20:24 - Why Joining SubTo and Gator is a Game-Changer   Join my Gator mentorship: http://joingatortribe.com/   Join Our Free Facebook Group: https://paceapproves.com/fbg-pod  

CME credits: 0.50 Valid until: 07-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/unlocking-the-potential-of-her3-targeted-therapy-breakthroughs-in-egfr-mutant-nsclc-therapeutic-approaches/16214/ Dive into the forefront of precision oncology with Drs. Pasi Janne and Jyoti Patel, where they unravel the potential of HER3-directed antibody-drug conjugates (ADCs) in revolutionizing treatment for NSCLC. Discover the transformative potential of HER3-directed ADCs in overcoming resistance to EGFR-targeted TKI therapies. This program offers a unique blend of trial results and practical strategies through the lens of a clinical case. Join us to lead the change in cancer care.=

Dr. Jyoti Patel and Dr. Natasha Leighl discuss the latest full update to the stage IV NSCLC without driver alterations living guideline. This guideline addresses first-, second-, and subsequent-line therapy for patients according to their histology (squamous cell and nonsquamous cell carcinomas) and PD-L1 expression. They discuss the streamlined recommendations, incorporation of recent evidence, and the highlights for implementation of these recommendations in the treatment of advanced non-small lung cancer. Dr. Patel and Dr. Leighl also point out ongoing trials that will inform this continuously updated guideline as we look ahead.  Read the full update, “Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3” at www.asco.org/living-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/living-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO.23.02746.    Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts  delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all of our shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Jyoti Patel and Dr. Natasha Leighl, co-chairs on “Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3.” Thank you for being here, Dr. Patel and Dr. Leighl. Before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Patel and Dr. Leighl, who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes.  So, to start us off on the content of this episode, Dr. Patel, this living clinical practice guideline for systemic therapy for patients with stage IV non-small cell lung cancer without driver alterations is being updated on a regular basis. Could you provide some background information on the process for these living guidelines? Dr. Jyoti Patel: The ASCO Living Guideline offers continually updated recommendations based on review of systemic randomized controlled trials. We bring a panel of experts together that includes representatives from Ontario Health as well as ASCO patient representatives. We review phase III studies and other published studies between the times from July 2022 and October 2023 for this most updated guideline. We think about the size of the populations that are being tested, what kind of interventions we have, the outcomes. We certainly look at PFS, as well as OS, but also toxicity, and overall response rates. We prioritize randomized trials and really look for studies that have large sample sizes. We exclude studies that were only meeting abstracts and really look at those that are published in peer-reviewed journals.  When we weigh the evidence, we really think about a number of factors. So what is the strength of the evidence, what's the sample size, and how we can make recommendations for our patients based on the totality of the data. Certainly, because this is such a rapidly evolving field, one of the things we are looking at is how to update in real-time these guidelines. So for this coming year, for example, these guidelines are published and we look forward to quarterly updates and, again, incorporate the latest evidence. Brittany Harvey: Great. Thank you for that explanation on the background and how these living guidelines are developed.  So, Dr. Leighl, could you describe what the key changes are from the expert panel? Dr. Natasha Leighl: So what we try to do in the guidelines for this latest publication, was really try and streamline the way we set up a format to make it much easier for people to use. In terms of new recommendations, we made sure to include more recent studies of additional PD-1 or PD-L1 inhibitors, for example, cemiplimab in combination with chemotherapy, or the combination of durvalumab and tremelimumab with chemotherapy, both of these in unselected patients, so with any PD-L1 expression, of course, this continues with pembrolizumab with or without chemotherapy, atezolizumab with chemotherapy combinations, and, of course,  nivolumab and ipilimumab with and without chemotherapy. And so it really is just an update on all of the potential options. In the discussion, we've really tried to go through some of the nuances in the trials just to help when you're discussing with patients or discussing with your oncologists, how to figure out which of these is best for you. Brittany Harvey: Excellent. It's helpful to have all of the recommendations listed out together so that clinicians and patients know all of the available options available to them.  So then, Dr. Patel, what should clinicians know as they implement these changes into their clinical practice? Dr. Jyoti Patel: I think it's important to stress that our decision-making in the treatment of advanced non-small cell lung cancer is really reliant on adequate biomarker testing. And so the way we approach this is our assumption that all appropriate patients undergo molecular testing and have PD-L1 testing to help us get the best therapies. And the other assumption is that patients and physicians are engaging in a dialogue to better assess patient preferences to have a better understanding of performance status, for example, as we think about allocating therapy. One thing that we've been able to do is to take the evidence and break it up by histology as well as PD-L1 expression for patients who don't have driver alterations. Based upon that, think about the toxicity data with, for example, dual immunotherapy versus chemo-immunotherapy for subsets of patients, and so hopefully get some guidance to clinicians as they are going through this process. The other part of the guideline was to, once again, look at second-line and subsequent therapies. So, again, for patients who get immunotherapy alone, the recommendation is that patients get a carboplatin-based doublet in the second-line setting. We still do not know if patients should get immunotherapy after that initial exposure, that is the subject of ongoing randomized studies. We also have stronger evidence than ever that docetaxel is an appropriate second-line agent, but there are other options there, so docetaxel and ramucirumab, as well as other single-agent chemotherapies. Brittany Harvey: Understood. Those are key points for informed and shared decision-making and are helpful for clinicians to know.  So then, Dr. Leighl, in your view, how will these guideline recommendations impact patients with non-small cell lung cancer without driver alterations? Dr. Natasha Leighl: Thanks. So, we're really hoping that with all of the focus in the first-line setting, that more patients will receive immunotherapy with or without chemotherapy in the first-line setting to really bring it forward and really make sure that patients can start benefiting as soon as possible. As Dr. Patel said, one of the challenges, of course, is to understand who might benefit most with a chemotherapy-free approach and have treatments in sequence versus who really needs everything together. And so, we've really tried in the discussion to try and help with that discussion both from a provider and patient perspective. So, we want more people to get immunotherapy to help improve their outcomes and also to potentially get it earlier. I think the other thing, and Dr. Patel has brought this up, but when we looked at what happens after first-line therapy, we really have very limited recommendations. And so it's our real hope that this will spur the community on to do even more studies to help us figure out what's next and how do we really improve outcomes for our patients after all of these great first-line options have stopped working. Brittany Harvey: Absolutely. I appreciate you touching on those key points for improved outcomes for patients with non-small cell lung cancer.   Finally, Dr. Patel, you have mentioned some ongoing randomized clinical trials and so has Dr. Leighl. So, what are the ongoing developments that the living guideline expert panel is monitoring for future updates? Dr. Jyoti Patel: We will continue to update guidelines based on available literature, but certainly, there are a number of trials that we should be reading out in the next year or so, looking at combinations of immunotherapy in the second-line setting. Certainly comparing novel agents to docetaxel in the second-line settings, and things like antibody-drug conjugates. So certaintly that's evidence that we hope to incorporate this evidence within the guideline with the idea that  we can really help clinicians and patients recognize or at least identify the best options for treatment for them.  Brittany Harvey: Definitely. Well, we'll look forward to the expert panel's review and interpretation of this evidence as those trials read out. And appreciate all of your work on this guideline update and we'll hear more as these guidelines are continuously updated. Thank you so much for your time today, Dr. Patel and Dr. Leighl.  Dr. Jyoti Patel: Thank you. Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to asco.org/living-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experiences, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    

Dr. Natash Leighl and Dr. Jyoti Patel are back on the podcast to discuss the update to the living guideline on stage IV NSCLC with driver alterations. This guideline includes recommendations for first-, second-, and subsequent-line therapy for patients with driver alterations including: EGFR, ALK, ROS1, BRAFV600E, MET exon skipping mutation, RET rearrangement, NTRK rearrangement, HER2, and KRAS G12C. They highlight the key changes to the recommendations, addition of recent trials, the importance of biomarker testing, and the impact of this guideline for clinicians and patients living with advanced NSCLC. Stay tuned for future updates to this continuously updated guideline. Read the full update, “Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3” at www.asco.org/living-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/living-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO.23.02744.    Brittany Harvey: Hello, and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts.    My name is Brittany Harvey, and today I am interviewing Dr. Jyoti Patel and Dr. Natasha Leighl, co-chairs on “Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3.” Thank you for being here, Dr. Patel and Dr. Leighl.  And before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Patel and Dr. Leighl, who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So, to start us off on this living clinical practice guideline, Dr. Leighl, this guideline for systemic therapy for patients with stage four non-small cell lung cancer with driver alterations is being routinely updated. What new data was reviewed in this full update to the living guideline? Dr. Natasha Leighl: Thanks so much, Brittany. So, we looked through the literature for publications between February and the end of October 2023, and also any novel agents that were approved, in particular by the United States FDA, to really incorporate this update in the current guidelines. In particular, we had updates in EGFR-driven tumors, BRAF and RET-driven tumors. And we also worked very hard to make this more digestible. In particular, it was turning into a bit of a laundry list of all of the things that we had ever recommended. So we really wanted to shorten things, pare them down, and really make them helpful and very, very current for the treatment of people with lung cancer in 2023 and 2024. Brittany Harvey: Excellent. Thank you for providing that overview of the evidence reviewed and the key updates that we will address in this guideline. So then I would like to talk about some of those key updated recommendations from the expert panel. You mentioned both EGFR, BRAF, and RET. So starting with patients with stage IV non-small cell lung cancer with EGFR alterations, Dr. Leighl, what are the key changes to those recommendations? Dr. Natasha Leighl: So, as I said, we really started to get quite a long list of things we recommended, including drugs that, to be honest, we no longer think are what we should lead with first-line. So we updated the recommendation to recommend first-line osimertinib in patients with sensitizing mutations. We were also able to capture in this update for patients with EGFR exon 20 insertion mutant lung cancer, the data from the randomized PAPILLON trial, recommending amivantamab plus chemotherapy for progression-free survival benefit. Not yet an overall survival benefit, but we will see how these data mature.  The other thing that we did was we moved all of the- I don't want to call them "legacy agents" because, in many countries, these are still very important. But older agents such as gefitinib, approaches such as gefitinib plus chemotherapy, and drugs like dacomitinib and other agents where we truly believe as an international panel that we would prefer a third-generation kinase inhibitor like osimertinib. We moved all of those to our discussion, just to recognize that, around the world, not everybody may have access. And we also specified that things are different in different countries. So, for example, in China, there are other third-generation kinase inhibitors with randomized data to support their use. And those are approved and used in China. And also, for example, in Korea, there are other agents that are used. So, we have really tried to be both inclusive and yet keep things simple at the same time. And hopefully, we have succeeded.  One of the challenges was that, with all of the updates that we made, we did not have all of the publications out yet at the end of October to make recommendations about moving beyond osimertinib in the first-line setting. So, please stay tuned for the next guideline update, where we're going to tackle whether we should give osimertinib alone or combination therapy. Brittany Harvey: Excellent. Thank you for providing those updates and clarifications for those patients with non-small cell lung cancer and an EGFR alteration. And we will look forward to the guideline panel's review of that evidence and future updates as well. So then, Dr. Leighl, you had previously mentioned that additional recommendations were updated, such as those for patients with BRAF alterations and RET alterations. So, Dr. Patel, what are the other key updated recommendations from the expert panel? Dr. Jyoti Patel: Thanks so much, Brittany. So certainly, I think we have seen many of these trials mature over time, which has been fantastic. I think one remarkable achievement was the reporting of a phase III selpercatinib trial. This was a trial in the front-line setting, in which patients who were RET-positive were randomized to selpercatinib versus carboplatin-based chemotherapy. And the selpercatinib significantly outperformed platinum-based chemotherapy, and I think really demonstrated a significant improvement in progression-free survival. So, based on that phase III trial, the recommendation for selpercatinib was elevated. Many of these agents that are used in clinical practice are approved initially on smaller phase I or phase II trials. And so, seeing the maturity of these phase III trials gives clinicians and patients greater certainty that these agents are really effective. And so, the evidence was increased for that, and that's now a preferred agent over another TKI, pralsetinib, in which there is only phase II data. So, certainly, those kinds of real things that we can explain to patients are important in these guidelines.  Another thing that we were able to update was another doublet for BRAF V600E non-small cell lung cancer. So, the combination of the two TKIs, encorafenib and binimetinib, was also included in the guidelines.  One thing that we tried to help was really identifying the best therapy post-progression on these first-generation TKIs. And again, there is a paucity of data, but often we went back to carboplatin-based doublets, and there is some data regarding whether or not patients with driver alterations should get immunotherapy in the second-line setting. And so, certainly, I think we have a number of randomized studies for patients with classical EGFR mutations, and our recommendation is generally avoidance of immunotherapy for these patients and treating many of these patients with carboplatin and pemetrexed when appropriate. I do not think we have the data for a lot of other subsets of patients. So, again, stay tuned as these data evolve. Brittany Harvey: Thank you for reviewing those updated recommendations and the supporting evidence. I think it's helpful for our listeners to understand the level of evidence behind these recommendations as well.  So then, Dr. Leighl, what should clinicians know as they implement these new and updated recommendations? Dr. Natasha Leighl: It's really important, first of all, to make sure that you have the information that you need to get your patients to these great new treatments as part of the shared decision-making process. So your patients need biomarker testing. You need to get that as quickly as you can. As Dr. Patel has highlighted, you really want to get that before they start their first-line therapy, if at all possible. We also really tried to bring out in this guideline that when things are delayed, I mean, this is the real world that we live in, just to be very cautious of immunotherapy with chemotherapy for that first cycle. That obviously, again, is a discussion with your patient, but this concept that the approach of a cycle of chemotherapy while you wait for the next-generation sequencing testing. And then if the patient does not have a driver alteration, adding any other therapy as appropriate is okay. It's something that people do. We believe it's important as we talk about the balance between benefits and harms. And so I think that's in there for clinicians, and I hope that they and patients can really benefit from that to avoid toxicity and also to really improve the ability to get molecular testing results first line.  Also, I think it's really important that when people read the wording of the guidelines, that this really follows GRADE, which is a type of system that we use to develop our recommendations. And so things like "may" do not mean that you shouldn't do it. So sometimes we'll hear back from clinicians and say, "Well, you said that they may use alectinib or lorlatinib, for example, with ALK, and I can only get coverage for one or the other." And so I think it's really important that clinicians and patients recognize that all of the things that we do recommend, even if we do use the word "may" or the recommendation is more conditional, we do think that these agents should be available for patients and clinicians, and that they go through this shared decision-making process together.  And so I think that's something that clinicians, we hope, can help take forward as they advocate for their patients to get access to these different and new and emerging treatments that have clearly shown benefit. Even when we say patients and clinicians may use this or that, there may be excellent reasons for using something newer, that's emerged, perhaps for toxicity benefits or benefits in terms of efficacy, even though we can't compare directly. And so we really want clinicians and patients to be empowered to access these new compounds and these new exciting agents that are in our guidelines. Brittany Harvey: Absolutely. Thank you for reviewing those key points. And, yes, that's a great comment that the level of obligation in the recommendations may be based on the evidence quality, but that doesn't mean that clinicians and patients shouldn't have access to all of the recommended treatment options to offer patients based off their individual patient and clinical characteristics.  So then, Dr. Patel, in your view, how will these changes affect patients with non-small cell lung cancer, with driver alterations?  Dr. Jyoti Patel: A lot of this echoes the points made by Dr. Leighl. I think there are opportunities for patients to assess toxicity or what it means for intensification of therapy. So, particularly for EGFR patients, for example, we have data that chemotherapy with osimertinib can improve progression-free survival, or the incorporation of a bispecific antibody, amivantamab, can improve progression-free survival over the TKI alone. It certainly comes with increased toxicity. And so how we weigh this in the absence of a known survival benefit at this juncture is one that, again, really gives patients the opportunity to prioritize what's important for them. And so I think this guideline affects patients and that we have multiple options, we help with the weight of the evidence so they may be able to better discern what treatment makes sense for them. Brittany Harvey: Understood. Yes, this guideline provides lots of options for different patients based off their driver alterations. So it's helpful to have that information for shared decision-making with their clinicians.  So then finally, to wrap us up, Dr. Leighl, what current research is the living guideline expert panel monitoring for updates to the guideline recommendations? Dr. Natasha Leighl: This process of the living guidelines has really been to help us stay on top of the amazing and incredibly rapid progress that we're making in lung cancer and other cancers. And even with this process, where we're trying to stay up-to-the-minute, there have already been some changes in the literature between the start of November and now. And so we're already working on some additional commentary and options for the first-line treatment of patients with EGFR-mutant lung cancer. Also, the subsequent treatment of patients with EGFR-mutant lung cancer, depending on what they've had before. Also, a great new study in patients with ROS1 fusion-driven lung cancer. And so these are some of the things that we're looking at.   Also, a bit more discussion about the importance of molecular testing. In our companion article, the Journal of Oncology Practice, along with Dr. Patel, we're going to be talking a bit more about new ways to genotype, for example, using both liquid biopsy and tumor tissue at the same time, and some of the support for that and how it gets us with our patients to the answers that they need faster.  Brittany Harvey: Absolutely. The pace of research in non-small cell lung cancer has moved quite quickly. So we definitely appreciate the panel's efforts to review all of this evidence on a continuous basis and take the time to develop these guideline recommendations for both clinicians and patients with non-small cell lung cancer.  So I want to thank you so much for your work to update these guidelines, and thank you for your time today, Dr. Patel and Dr. Leighl. Dr. Natasha Leighl: Thanks so much. It's a real pleasure to be here. Dr. Jyoti Patel: Thank you.  Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/living-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast, and be sure to subscribe so you never miss an episode.  The purpose of this podcast is to educate and inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

On this episode of The Bookkeepers' Podcast Jo Wood and Zoe Whitman will be joined by Jyoti Patel from Xero to talk about how storytelling can help you to gain new clients. The role of the bookkeeper has changed over the years. In today's world, bookkeepers are not just expected to manage finances but also help their clients grow their businesses. To achieve this, bookkeepers need to learn how to communicate effectively and engage with their clients. This is where storytelling comes in - it is a powerful tool to connect with the audience and convey complex ideas in a simple and memorable way. In this podcast, we explored how storytelling is important for marketing. Storytelling is not just about telling a story; it's about creating an emotional connection with the audience. By sharing experiences, anecdotes, and personal insights, bookkeepers can get their clients to relate to them and build trust. This makes it easier for clients to open up about their business challenges and enables bookkeepers to offer relevant solutions. The idea is to make the client feel like they are not alone in their journey - that there are others out there going through the same struggles. About us We help bookkeepers find clients, make more money and build businesses they love that work for them. We're raising the profile of the bookkeeping profession and bookkeepers worldwide. Whether you're a bookkeeper or accountant wanting to grow your own business to have the flexibility for your life, and your family, come and join us. Join our FREE Facebook community, The 6 Figure Bookkeepers' Club, to experience this revolution for yourself. Connect with us at 6figurebookkeeper.club ----------------------------------------------- Quiz Are you 6 figure ready? Find out at 6figurebookkeeper.scoreapp.com ----------------------------------------------- Courses Find out about how we can help you at 6figurebookkeeper.com/bookkeeper-courses ----------------------------------------------- About our Sponsor This episode of The Bookkeepers' Podcast is sponsored by Xero. Find out more at: https://www.xero.com/uk/campaign/new-partner-programme/?utm_source=6FB&utm_medium=podcastnotes&utm_campaign=Q2 ----------------------------------------------- The information contained in The Bookkeepers' Podcast is provided for information purposes only. The contents of The Bookkeepers' Podcast is not intended to amount to advice and you should not rely on any of the contents of the Bookkeepers' Podcast. Professional advice should be obtained before taking or refraining from taking any action as a result of the contents of the Bookkeepers' Podcast. The 6 Figure Bookkeeper Ltd disclaims all liability and responsibility arising from any reliance placed on any of the contents of the Bookkeepers' Podcast. ------------------

Dr. Jyoti Patel is a triple board certified physician in integrative pediatrics, internal medicine, and integrative & functional medicine. Dr. Patel was named one of the TOP DOCS in Phoenix Magazine 2009, 2016, 2022, Internist of the Year 2011 by the American College of Physicians Arizona Chapter and she received the Women In White Coats Hero Award in 2019.   She spearheaded a community garden in Fountain Hills, AZ and she was awarded the Healthcare Provider of the Year 2017 by the Fountain Hills Chamber of Commerce and Volunteer of the Year Award 2018 by the Town of Fountain Hills. S She is certified in Functional Medicine by IFM, is a Qualified MBSR teacher through UCSD and a Chopra Certified Ayurvedic Lifestyle Practitioner. Dr. Patel has a special interest in Corporate Wellness, Ayurvedic Retreats, Integrative Medicine, Functional Medicine, Mindfulness-Based Stress Reduction, and medical cosmetics. Instagram TikTok Resources mention in the show: Jyoti Patel,, MD on Medicine Redefined (Episode 3) SOMA Breathwork SHIFT Breathwork Test The Comfort Crisis - Book Breath - Book The Microbiome in Health and Disease from the Perspective of Modern Medicine and Ayurveda Andrew Huberman Physiologic Sigh Andrew Weil's 4-7-8 Breathwork Wim Hof Method

Imagine you—or a loved one—receives a cancer diagnosis. Overnight, you find yourself trying to become an oncology expert, desperately looking for information about options. You stumble across a research paper that looks promising—if you could make sense of all the science-speak. Then you find Cancer.Net, the patient information website of Conquer Cancer and the American Society of Clinical Oncology (ASCO). This doctor-approved resource makes cancer terminology easier to digest and offers the latest guidelines on research and treatment. In this episode of Your Stories, host and cancer survivor Brenda Brody is joined by Dr. Jyoti Patel, a clinical oncologist and the editor-in-chief of Cancer.Net. Together, they unpack some of the year's biggest research breakthroughs, explain what makes these findings meaningful for patients, and talk about the long-term impact of donor-funded research. They also share why providing cancer information in lay terms is essential to raising awareness and support.

Dr. Jyoti Patel, Director of Thoracic Oncology and member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern Medicine, joins Lisa Dent to talk about ways to spot early signs of lung cancer, and understanding why it’s paramount to undergo screenings early. Follow The Lisa Dent Show on Twitter:Follow @LisaDentSpeaksFollow @SteveBertrand Follow @kpowell720 Follow […]

This week on the Penguin Podcast, Nihal Arthanayake is joined by the second winner of Stormzy's Merky Books Prize, and she was also one of the Observer's best new novelists, it's Jyoti Patel.Jyoti joins us to discuss her debut novel, The Things That We Lost, a story of family, loss and how far we go to protect those we love.Also discussed on the podcast is the experience of mixing British and Gujarati cultures, the privilege of studying the arts, the importance of being your authentic self, the idea of the perfect sentence, and where it is that Jyoti feels the writer's life most intensely. Don't forget to subscribe so you never miss an episode, and please do leave us a review – it really does help us. And finally, to find out more about the #PenguinPodcast, visit https://www.penguin.co.uk/podcasts. Hosted on Acast. See acast.com/privacy for more information.

In this episode we sit with Jyoti who tells us all about her Kenyan Gujarati heritage and the role it has played in writing her debut novel 'The Things That We Lost'. Grab a copy wherever you purchase your books. https://www.waterstones.com/book/the-... IG: @jyotisbooks @wearemediahive

An Ohio Mysteries/Akron Beacon Journal crossover In 1991, Manher and Jyoti Patel and their 6-year-old daughter Alka were executed in their home in Green. The Patels owned the notorious pay-by-the-hour Steve's Motel. Summit County detectives have come to believe it was a professional hit over a business deal - and for the first time name their suspected triggermen. Ohio Mysteries: http://www.ohiomysteries.com Akron Beacon Journal: http://www.beaconjournal.com Ross Bugdon Music https://www.youtube.com/c/RossBugden Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of Confessions of a Debut Novelist, I'm talking to Jyoti Patel about her contemporary novel The Things That We Lost. In this episode we talk about how Jyoti's Merky Books prize win lead to publication, the importance of taking yourself seriously as a writer and how small tweaks to dialogue and using slang gave authenticity to her teenage protagonist. Confessions of a Debut Novelist Bookshop*Buy The Things That We Lost: https://uk.bookshop.org/a/10990/9781529186338Follow Jyoti on Twitter: @Jyoti__Patelhttps://linktr.ee/jyotisbooksFollow Chloe on Twitter: @clotimmsBuy Chloe's debut novel The Seawomen: https://linktr.ee/chloetimmschloetimms.co.uk *affiliate link - if you buy books linked to the Bookshop.org site, I may earn a commission. Hosted on Acast. See acast.com/privacy for more information.

“I didn't write this book to be hugely sellable, hugely commercial - I wrote it because it's a story that I felt needed to be told.” Jyoti Patel's debut novel, ‘The Things That We Lost' is the story of a British Gujarati mother and son discovering how they fit into the world and learning how to balance the Gujarati and British sides of their identities.  The book earnt Jyoti the Merky Books New Writers Prize 2021, a competition launched by Stormzy and Penguin House UK to discover unpublished and underrepresented writers.  In this episode, Jyoti joins Krishnan to talk about feeling othered, why her book is written in the voice of a young man, and how to ask someone the question, “where are you from?”  Produced by: Imahn Robertson

In this episode, I chat to the lovely Jyoti Patel, author of the Merky Books Young Writer's Prize for 2021. Her debut novel is a stunning, moving coming-of-age story of a British-Gujarati family living in North London. The Things That We Lost s told from the perspectives of 18-year-old Nik and his British Indian mother Avani, flitting between the past and present as Nik searches for answers surrounding the circumstances of his father's death. An extract of the novel was selected as the winning submission out of over 2000 entries for the 2021 #Merky Books New Writers' Prize.Earlier this month, Jyoti was selected as one of The Observer's 10 Best New Novelists for 2023. She is also a graduate of the Creative Writing Prose Fiction MA from the University of East Anglia and she joins us today from London. In this episode, we talk about family dynamics, secrets, mental health, identity, language and being asked where we're from.Connect with me on instagram:www.instagram.com/thediversebookshelfpodwww.instagram.com/readwithsamia Support the show

Tár is a psychological drama about an imaginary conductor, Lydia Tár, which has already made waves both for its central performance by Cate Blanchett and for its striking, sometimes dreamlike story about the abuses of power. It is tipped for awards and Cate Blanchett has already won the Golden Globe for her performance. The writer and director, Todd Field, joins Front Row. The news that the celebrated opera company Glyndebourne has cancelled its national tour for 2023, due to the recent cut to its Arts Council funding, was received as the latest bombshell on the UK's opera landscape. Glyndebourne's artistic director, Stephen Langridge, and the music writer and critic Norman Lebrecht discuss the company's decision and explore what kind of support and vision opera in the UK needs. Jyoti Patel on winning musician Stormzy's Merky Books New Writer's Prize in 2021 and now making her debut as novelist with her book, The Things We Have Lost. Continuing Front Row's look at the shortlist for this year's TS Eliot Prize For Poetry, today Anthony Joseph reads from his collection Sonnets For Albert – poems exploring being the Trinidad-born son of a mostly-absent father. The poem is called El Socorro. Presenter: Shahidha Bari Producer: Emma Wallace Main Image Credit: Cate Blanchett as Lydia Tár - Universal

CME credits: 0.25 Valid until: 02-11-2023 Claim your CME credit at https://reachmd.com/programs/cme/patient-centered-discussions-and-shared-decision-making-in-the-management-of-nsclc-with-metex14-skipping-mutations/14088/ Join us as Dr. Jyoti Patel illustrates her approach to treating a 75-year-old patient who was recently diagnosed with stage IV NSCLC harboring a MET exon 14 skipping mutation—then put these tips to use in your own practice!

Lung Cancer Considered Host Dr. Stephen Liu leads a recap of the recently completed IASLC 2022 North America Conference on Lung Cancer featuring guests Dr. Jessica Donington, Professor and Chief Thoracic Surgery University of Chicago; Dr.Jyoti Patel, Thoracic Medical Oncology, Robert H Lurie Comprehensive Cancer Center, Northwestern University and Dr. Shruti Patel, Oncology Fellow at Stanford School of Medicine.

Career transitions are normal in academic oncology, oncology practice, and industry and today's oncologists go through a number of 'job' interviews during their post-graduate life and early career. In this episode of Lung Cancer Considered, host Dr. Narjust Florez discusses how to find or transition to that new job in thoracic oncology. Joining the discussion are three lung cancer researchers: Dr. Mark Awad, clinical director of the Thoracic Oncology Group at Dana Farber Cancer Institute, assistant professor of Medicine at Harvard Medical School and a leading researcher in KRAS-mutant NSCLC. Dr. Ana Velazquez, instructor of medicine and thoracic medical oncologist at UCSF and a postdoctoral fellow at the National Clinical Scholars Program. Dr. Velazquez is completing her training and searching for her faculty position. Dr. Jyoti Patel, associate vice for clinical research, a thoracic medical oncologist, and professor of medicine at Northwestern University in Chicago. Dr. Patel is a leader in thoracic oncology, focusing her efforts on the development and evaluation of novel molecular markers and therapeutics for patients with non-small cell lung cancer.

Dr. Patel was named one of the TOP DOCS in Phoenix Magazine 2009, 2016, Internist of the Year 2011 by the American College of Physicians Arizona Chapter and she received the Women In White Coats Hero Award in 2019.   She spearheaded a community garden in Fountain Hills, AZ and she was awarded the Healthcare Provider of the Year 2017 by the Fountain Hills Chamber of Commerce and Volunteer of the Year Award 2018 by the Town of Fountain Hills. She is a Fellow of the American College of Physicians and the American Academy of Pediatrics. She is uniquely trained, triple board-certified, and practices Integrative Pediatrics and Internal Medicine in Scottsdale, Arizona. She is certified in Functional Medicine by IFM, is a Qualified MBSR teacher through UCSD and a Chopra Certified Ayurvedic Lifestyle Practitioner. Dr. Patel has a special interest in Corporate Wellness, Ayurvedic Retreats, Integrative Medicine, Functional Medicine, Mindfulness-Based Stress Reduction, and medical cosmetics. She can be reached at https://aimsforwellness.com/

When was the last time you felt a sense of play at work?  Our current workplace paradigms and power structures no longer serve us, and we're called to rethink them to have more impact and financial success. My guests today are Jyoti Patel and Emily Griffin. These two powerhouses joined together to create The Empathy Tour, where they spent the fall of 2020 talking to all types of leaders, both traditional ones and those underrepresented in the business world, to talk about how they lead, what challenges they face, and the very real ways they are having impact and success through empathy. Today, they share what role play has in organizational success and the common misconceptions of what we mean by a playful culture. We examine how you can embody play to foster impact and collaboration. They share best practices about creative facilitation and experience design and how they teach teams to be in creative flow. We also discuss the barriers that exist to creating more inclusive, empathetic cultures, and what they learned from leaders during The Empathy Tour on how to get past them. If you are a leader in any capacity or industry, this episode is not to be missed! Key Takeaways:Play opens up creativity and imagination, and it decreases the fear of judgment, as well as the pressure and tension of the day-to-day work dynamics. Innovation does not come when employees are being constrained. Play creates an opening for everybody to speak up and participate.Play is an art - do it for its own sake. The first step is listening and making it safe for employees to share their feedback, whether that's anonymously, or openly in a team setting. "Play really opens up the team process, it opens up the human element, it makes empathy and creativity center to a team facilitation process rather than on the side. Ultimately, you end up with results that folks can really get on board with." —  Jyoti Patel About Jyoti Patel and Emily Griffin:Jyoti Patel - Principal and Owner, Spille LLCI teach leaders and teams to harness greater power using empathy, creativity, & systems thinking.I integrate my identities as a global leader of change, a woman of color, an artist, and a mother to design experiences that are inclusive, innovative, and delivered in the context of complex, technical work.For the first act of my career, I led integrated flight test engineering teams, global design/build teams, enterprise learning & development programs, and deep transformations across commercial and defense test programs at a Fortune 50 company. I was on an executive track, when I decided to leave to start my own consultancy.I design and deliver experiences that address the systemic dysfunctions I experienced during my corporate management tenure, including short-term, myopic thinking, systemic bias, poor communication, lack of team alignment, and resistance to change.I believe culture and strategy development is a team sport, and people support what they help create Emily GriffinEmily Griffin is a multidimensional producer with roots in broadcasting, publishing & DJing. She's led global creative teams in technology, art & entertainment for over 20 years, conducting an array of events, campaigns, courses and digital products. Woven into her professional accomplishments is her commitment to embodiment, healing and transformation. As DJ GriffinGrrl, her ongoing collaborations within the dance music community continue to uplift and inspire. Emily brings her unmatched energy and an empathetic approach to her new consultancy Emily Griffin & Co, offering creative leadership, experience design & facilitation. Connect with Jyoti and Emily:Website: https://www.spilleplay.comWebsite: www.emilygriffin.coDownload your free guidebook with prompts and lessons from leaders: www.theempathytour.coTwitter: https://twitter.com/spilleplayLinkedIn: https://www.linkedin.com/in/jyotibflyFacebook: https://www.facebook.com/spilleplayInstagram: www.instagram.com/spilleplay The Empathy Tour:LinkedIn: https://www.linkedin.com/showcase/theempathytour/Instagram: https://www.instagram.com/theempathytour/Twitter: ​​https://twitter.com/EmpathyTourFacebook: https://www.facebook.com/theempathytour Don't forget to download your free guide! Discover The 5 Business Benefits of Empathy: http://red-slice.com/business-benefits-empathy Connect with Maria: Get the podcast and book: TheEmpathyEdge.comLearn more about Maria's brand strategy work and books: Red-Slice.comHire Maria to speak at your next event: Red-Slice.com/Speaker-Maria-RossTake my LinkedIn Learning Course! Leading with EmpathyLinkedIn: Maria RossInstagram: @redslicemariaTwitter: @redsliceFacebook: Red Slice

When was the last time you felt a sense of play at work?  Our current workplace paradigms and power structures no longer serve us, and we're called to rethink them to have more impact and financial success. My guests today are Jyoti Patel and Emily Griffin. These two powerhouses joined together to create The Empathy Tour, where they spent the fall of 2020 talking to all types of leaders, both traditional ones and those underrepresented in the business world, to talk about how they lead, what challenges they face, and the very real ways they are having impact and success through empathy. Today, they share what role play has in organizational success and the common misconceptions of what we mean by a playful culture. We examine how you can embody play to foster impact and collaboration. They share best practices about creative facilitation and experience design and how they teach teams to be in creative flow. We also discuss the barriers that exist to creating more inclusive, empathetic cultures, and what they learned from leaders during The Empathy Tour on how to get past them. If you are a leader in any capacity or industry, this episode is not to be missed! Key Takeaways:Play opens up creativity and imagination, and it decreases the fear of judgment, as well as the pressure and tension of the day-to-day work dynamics. Innovation does not come when employees are being constrained. Play creates an opening for everybody to speak up and participate.Play is an art - do it for its own sake. The first step is listening and making it safe for employees to share their feedback, whether that's anonymously, or openly in a team setting. "Play really opens up the team process, it opens up the human element, it makes empathy and creativity center to a team facilitation process rather than on the side. Ultimately, you end up with results that folks can really get on board with." —  Jyoti Patel About Jyoti Patel and Emily Griffin:Jyoti Patel - Principal and Owner, Spille LLCI teach leaders and teams to harness greater power using empathy, creativity, & systems thinking.I integrate my identities as a global leader of change, a woman of color, an artist, and a mother to design experiences that are inclusive, innovative, and delivered in the context of complex, technical work.For the first act of my career, I led integrated flight test engineering teams, global design/build teams, enterprise learning & development programs, and deep transformations across commercial and defense test programs at a Fortune 50 company. I was on an executive track, when I decided to leave to start my own consultancy.I design and deliver experiences that address the systemic dysfunctions I experienced during my corporate management tenure, including short-term, myopic thinking, systemic bias, poor communication, lack of team alignment, and resistance to change.I believe culture and strategy development is a team sport, and people support what they help create Emily GriffinEmily Griffin is a multidimensional producer with roots in broadcasting, publishing & DJing. She's led global creative teams in technology, art & entertainment for over 20 years, conducting an array of events, campaigns, courses and digital products. Woven into her professional accomplishments is her commitment to embodiment, healing and transformation. As DJ GriffinGrrl, her ongoing collaborations within the dance music community continue to uplift and inspire. Emily brings her unmatched energy and an empathetic approach to her new consultancy Emily Griffin & Co, offering creative leadership, experience design & facilitation. Connect with Jyoti and Emily:Website: https://www.spilleplay.comWebsite: www.emilygriffin.coDownload your free guidebook with prompts and lessons from leaders: www.theempathytour.coTwitter: https://twitter.com/spilleplayLinkedIn: https://www.linkedin.com/in/jyotibflyFacebook: https://www.facebook.com/spilleplayInstagram: www.instagram.com/spilleplay The Empathy Tour:LinkedIn: https://www.linkedin.com/showcase/theempathytour/Instagram: https://www.instagram.com/theempathytour/Twitter: ​​https://twitter.com/EmpathyTourFacebook: https://www.facebook.com/theempathytour Don't forget to download your free guide! Discover The 5 Business Benefits of Empathy: http://red-slice.com/business-benefits-empathy Connect with Maria: Get the podcast and book: TheEmpathyEdge.comLearn more about Maria's brand strategy work and books: Red-Slice.comHire Maria to speak at your next event: Red-Slice.com/Speaker-Maria-RossTake my LinkedIn Learning Course! Leading with EmpathyLinkedIn: Maria RossInstagram: @redslicemariaTwitter: @redsliceFacebook: Red Slice

An Ohio Mysteries/Akron Beacon Journal crossover In 1991, Manher and Jyoti Patel and their 6-year-old daughter Alka were executed in their home in Green. The Patels owned the notorious pay-by-the-hour Steve's Motel. Summit County detectives have come to believe it was a professional hit over a business deal - and for the first time name their suspected triggermen. Ohio Mysteries: http://www.ohiomysteries.com Akron Beacon Journal: http://www.beaconjournal.com Ross Bugdon Music https://www.youtube.com/c/RossBugden

Welcome to Off the Shelf! You can follow me on Instagram here: Phoebe @ Pause Books HQ (@pausebooks)  You can follow me on Twitter: Phoebe @ Pause Books HQ (@PauseBooks)  My guest this week is Jyoti Patel: You can follow her on Instagram here: Jyoti Patel (@jyotisbooks)  You can follow her on Twitter here: Jyoti Patel (@Jyoti__Patel)  You can read her short story with We Present here: https://wepresent.wetransfer.com/story/literally-jyoti-patel/ If you want to know more about her writing then you can read a Q&A here: https://www.thebookseller.com/insight/jyoti-patel-1274276 Her book choices are: Burnt Sugar by Avni Doshi  Natives by Akala  In The Days of Rain by Rebecca Stott The Palace of Illusions by Chitra Banerjee Divakaruni  On Chesil Beach by Ian McEwan The Penguin podcast with Avni Doshi that we discuss can be heard here: https://podcasts.apple.com/gb/podcast/avni-doshi-with-nihal-arthanayake/id89411073?i=1000526562160

Dr. Jyoti Patel from Lurie Cancer Center, Northwestern University joins Drs. Charu Aggarwal & Jack West to reflect on how to decide when to change institutions, & the evolving methods of providing cancer education, including directly to patients.

For the fourteenth episode of The Literary Edit Podcast, I was joined by author Jyoti Patel, winner of the second #Merky Books New Writers Prize, for her forthcoming novel, Six of One. She also wrote short story Break for We Transfer's Literally platform.   You can read about Jyoti's Desert Island Books here, and the ones we discuss in this episode are:   The Namesake by Jhumpa Lahiri Shuggie Bain by Douglas Stuart Emergency Kit: Poems For Strange Times, edited by Jo Shapcott & Matthew Sweeney Atonement by Ian McEwan The Good Immigrant, edited by Nikesh Shukla Open Water by Caleb Azumah Nelson Why I'm No Longer Talking to White People About Race by Reni Eddo-Lodge The Boy, The Mole, The Fox and The Horse by Charlie Mackesy   Other books we spoke about included Transcendent Kingdom by Yaa Gyasi, The Picture of Dorian Gray by Oscar Wilde, On Chesil Beach by Ian McEwan, The Season of Phantasmal Peace by Derek Walcott and That Reminds Me by Derek Owusu.   If you'd like to buy any of the books we discussed in the episode, please consider doing so from the list I created on Bookshop.org, an online bookstore with a mission to financially support local, independent bookstores. If you're based in Australia, please consider buying them from Gertrude & Alice, who deliver all over the country. To contact me, email lucy@thelitedit.com   Facebook The Literary Edit   Instagram: @the_litedit @jyotisbooks   Twitter: @thelitedit @jyoti_patel    

Welcome to the Doctor Me First Summer Showcase where we are spotlighting the other amazing doctor podcasts that are out there. Over the next eight weeks you will get to listen to an episode from a different doctor podcast and then a solo podcast from me. This episode is from Medicine Redefined with Jyoti Patel, MD.   Our key takeaways from our discussion with Dr. Jyoti Patel. Jyoti Patel, MD

Prepare yourself for a mind-blowing episode as Dr. Carrie Lam, MD talks with Dr. Jyoti Patel, MD about how she is using integrative medicine approaches in Primary Care, making changes in the community through gardening and education, and fixing the gut using the functional medicine 5 R method. Remember that digesting doesn't just happen in the gut, but also in the mind.1:30 - Dr. Patel's journey in Integrative Medicine5:30 - Integrative Medicine in Primary Care8:40 - Community Garden10:15 - Group Visits12:00 - Healthy Food Access 15:30 - 5 R's of Gut Healing25:00 - Removal of Toxins27:00 - Replace with Enzymes or Acids or Fiber31:00 - Reinoculate the Microbiome33:30 - Repair the Gut Lining35:25 - Restore Mind-Body ConnectionTrying to find an integrative medicine or functional medicine doctor who understands what you're going through? Lam Clinic does Telemedicine all over the world and is only a phone call away. 1. Educate yourself by visiting our website: www.lamclinic.com2. Call our office at 714-709-8000 to schedule an appointment. FIND US ONLINE HERE: » Website: https://www.lamclinic.com/» Facebook: https://www.facebook.com/lamclinic» Instagram: https://www.instagram.com/lam_clinic/» Tiktok: https://www.tiktok.com/@lamclinic» YouTube: https://www.youtube.com/channel/UCWtdb4L5h5EuxKvkNq3M7ywDr. Jyoti Patel's Information » Website: https://aimsforwellness.com/» Instagram: @drjyotipatelmd» Facebook: Jyoti Patel MD» TikTok: @jyotipatelmd

CME credits: 0.25 Valid until: 23-04-2022 Claim your CME credit at https://reachmd.com/programs/cme/liquid-and-tissue-biopsy-treatment-nsclc-focus-met-gene-aberrations/12465/ Lung cancer remains the most common cancer in the United States and Europe and second most common in Japan. Of patients with non-small cell lung cancer (NSCLC), approximately 3% to 4% have tumors that harbor MET gene aberrations including MET exon 14 skipping mutations. These patients have an even worse prognosis than others with NSCLC, and early diagnosis and targeted therapies are essential. Join us as Dr. Paul Paik and Dr. Jyoti Patel discuss the value that liquid biopsy brings to patients with NSCLC, specifically those with MET exon 14 skipping mutations.

CME credits: 0.25 Valid until: 23-04-2022 Claim your CME credit at https://reachmd.com/programs/cme/liquid-and-tissue-biopsy-treatment-nsclc-focus-met-gene-aberrations/12465/ Lung cancer remains the most common cancer in the United States and Europe and second most common in Japan. Of patients with non-small cell lung cancer (NSCLC), approximately 3% to 4% have tumors that harbor MET gene aberrations including MET exon 14 skipping mutations. These patients have an even worse prognosis than others with NSCLC, and early diagnosis and targeted therapies are essential. Join us as Dr. Paul Paik and Dr. Jyoti Patel discuss the value that liquid biopsy brings to patients with NSCLC, specifically those with MET exon 14 skipping mutations.

Host: Paul Paik, MD Guest: Jyoti D. Patel, MD, FASCO Lung cancer remains the most common cancer in the United States and Europe and second most common in Japan. Of patients with non-small cell lung cancer (NSCLC), approximately 3% to 4% have tumors that harbor MET gene aberrations including MET exon 14 skipping mutations. These patients have an even worse prognosis than others with NSCLC, and early diagnosis and targeted therapies are essential. Join us as Dr. Paul Paik and Dr. Jyoti Patel discuss the value that liquid biopsy brings to patients with NSCLC, specifically those with MET exon 14 skipping mutations.

Our key takeaways from our discussion with Dr. Jyoti Patel. Jyoti Patel, MD

Dr. Jyoti Patel joins us to open up about her personal journey through residency and practice, and how she unexpectedly fell into the fields of integrative and functional medicine. She talks about how her independent functional medicine practice allows her to approach her patients differently than conventional medicine. Last but not least, Dr. Patel shares tips on how to boost your immune system as the world protects itself from COVID-19. Jyoti Patel, MD

In this episode, a multidisciplinary panel of speakers discusses their experience and summarize the existing consensus statements for managing patients with suspected or confirmed lung cancer during the COVID-19 pandemic. Highlights of the discussion include: The impact of COVID-19 on standard of practice regarding timely diagnosis and staging Prioritization strategies related to surgery and invasive diagnostic and staging procedures Differences in radiation and systemic treatment strategies between pre-COVID and crisis times Alterations to standard treatment strategies based on existing experience and expert panel reports (Originally recorded September 3, 2020) Moderator: Septimiu D. Murgu, MD, FCCP Panelists: Jessica S. Donington, MD, MS; Jyoti Patel, MD; Andreas Rimner, MD; and Gerard A. Silvestri, MD, MS, FCCP For more tools to help in the fight against COVID-19, visit CHEST's COVID-19 Resource Center at chestnet.org/COVID19.